• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion.迷失在翻译中：科学与医疗保险覆盖标准对连续皮下胰岛素输注的脱节。
Diabetes Technol Ther. 2021 Oct;23(10):715-725. doi: 10.1089/dia.2021.0196. Epub 2021 Jun 17.
2
What's Wrong with This Picture? A Critical Review of Current Centers for Medicare & Medicaid Services Coverage Criteria for Continuous Glucose Monitoring.这张图有什么问题？对当前医疗保险和医疗补助服务中心连续血糖监测覆盖标准的批判性评价。
Diabetes Technol Ther. 2021 Sep;23(9):652-660. doi: 10.1089/dia.2021.0107. Epub 2021 Apr 27.
3
Increase Access, Reduce Disparities: Recommendations for Modifying Medicaid CGM Coverage Eligibility Criteria.增加可及性，减少差距：修改医疗补助连续血糖监测（CGM）覆盖资格标准的建议。
J Diabetes Sci Technol. 2024 Jul;18(4):974-987. doi: 10.1177/19322968221144052. Epub 2022 Dec 16.
4
Impact of Medicare Continuous Subcutaneous Insulin Infusion Policies in Patients With Type 1 Diabetes.医疗保险对 1 型糖尿病患者持续皮下胰岛素输注政策的影响。
J Diabetes Sci Technol. 2020 Mar;14(2):257-261. doi: 10.1177/1932296819838292. Epub 2019 Mar 31.
5
C-PEPTIDE AND BETA-CELL AUTOANTIBODY TESTING PRIOR TO INITIATING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION PUMP THERAPY DID NOT IMPROVE UTILIZATION OR MEDICAL COSTS AMONG OLDER ADULTS WITH DIABETES MELLITUS.在开始使用持续皮下胰岛素输注泵治疗之前，进行 C-肽和β细胞自身抗体检测并未改善老年糖尿病患者的利用率或医疗费用。
Endocr Pract. 2018 Jul;24(7):634-645. doi: 10.4158/EP-2017-0220. Epub 2018 May 31.
6
Impact of a tubeless, disposable insulin pump on emergency department visits and inpatient admissions among a Medicare population.一种无管、一次性胰岛素泵对 Medicare 人群中急诊就诊和住院入院的影响。
J Manag Care Spec Pharm. 2024 Oct;30(10):1128-1135. doi: 10.18553/jmcp.2024.23292. Epub 2024 Jun 17.
7
IMPROVED HBA1C, TOTAL DAILY INSULIN DOSE, AND TREATMENT SATISFACTION WITH INSULIN PUMP THERAPY COMPARED TO MULTIPLE DAILY INSULIN INJECTIONS IN PATIENTS WITH TYPE 2 DIABETES IRRESPECTIVE OF BASELINE C-PEPTIDE LEVELS.与多次皮下胰岛素注射相比，无论患者的基础 C 肽水平如何，胰岛素泵治疗均可改善 2 型糖尿病患者的糖化血红蛋白（HbA1c）、总日胰岛素剂量和治疗满意度。
Endocr Pract. 2018 May;24(5):446-452. doi: 10.4158/EP-2017-0234.
8
Resource utilization with insulin pump therapy for type 2 diabetes mellitus.胰岛素泵治疗 2 型糖尿病的资源利用。
Am J Manag Care. 2010;16(12):892-6.
9
Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps.持续皮下胰岛素输注治疗：胰岛素泵入门知识。
J Am Pharm Assoc (2003). 2009 Jan-Feb;49(1):e1-13; quiz e14-7. doi: 10.1331/JAphA.2009.08122.
10
[EFFECTIVENESS OF PUMP INSULIN THERAPY IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (REVIEW)].[胰岛素泵治疗2型糖尿病的有效性（综述）]
Georgian Med News. 2018 Nov(284):51-55.

引用本文的文献

1
The National Clinical Care Commission Report to Congress: Leveraging Federal Policies and Programs to Improve Diabetes Treatment and Reduce Complications.国家临床护理委员会向国会提交的报告：利用联邦政策和计划改善糖尿病治疗并减少并发症。
Diabetes Care. 2023 Feb 1;46(2):e51-e59. doi: 10.2337/dc22-0621.
2
Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations.支持 Medicare 和 Medicaid 1 型和 2 型糖尿病患者中串联控制-IQ 混合闭环成功的真实世界证据。
Diabetes Technol Ther. 2022 Nov;24(11):814-823. doi: 10.1089/dia.2022.0206. Epub 2022 Jul 26.
3
Barriers and Facilitators to Diabetes Device Adoption for People with Type 1 Diabetes.1 型糖尿病患者采用糖尿病设备的障碍和促进因素。
Curr Diab Rep. 2022 Jul;22(7):291-299. doi: 10.1007/s11892-022-01469-w. Epub 2022 May 6.
4
Barriers to Uptake of Insulin Technologies and Novel Solutions.胰岛素技术应用的障碍及新解决方案
Med Devices (Auckl). 2021 Nov 12;14:339-354. doi: 10.2147/MDER.S312858. eCollection 2021.

本文引用的文献

1
One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology.Control-IQ 高级混合闭环技术一年真实世界应用。
Diabetes Technol Ther. 2021 Sep;23(9):601-608. doi: 10.1089/dia.2021.0097. Epub 2021 Apr 21.
2
Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system.在接受无管路胰岛素管理系统治疗的 3592 名 2 型糖尿病患者中，血糖控制得到改善。
Diabetes Res Clin Pract. 2021 Apr;174:108735. doi: 10.1016/j.diabres.2021.108735. Epub 2021 Mar 9.
3
Association between hemoglobin A1c variability and hypoglycemia-related hospitalizations in veterans with diabetes mellitus.糖化血红蛋白变异性与糖尿病退伍军人低血糖相关住院的关系。
BMJ Open Diabetes Res Care. 2021 Jan;9(1). doi: 10.1136/bmjdrc-2020-001797.
4
First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 Diabetes.1 型糖尿病儿童和成人中具有可调血糖目标的无管自动化胰岛素输送系统的首次门诊评估。
Diabetes Technol Ther. 2021 Jun;23(6):410-424. doi: 10.1089/dia.2020.0546. Epub 2021 Jan 18.
5
Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications.肥胖、胰岛素抵抗与2型糖尿病：关联及治疗意义
Diabetes Metab Syndr Obes. 2020 Oct 9;13:3611-3616. doi: 10.2147/DMSO.S275898. eCollection 2020.
6
Treatment Satisfaction and Quality of Life among Type 2 Diabetes Patients: A Cross-Sectional Study in West Bank, Palestine.2型糖尿病患者的治疗满意度与生活质量：巴勒斯坦约旦河西岸的一项横断面研究
J Diabetes Res. 2020 Aug 25;2020:1834534. doi: 10.1155/2020/1834534. eCollection 2020.
7
Glycemic Control and Hypoglycemia in Patients Treated with Insulin Pump Therapy: An Observational Study.胰岛素泵治疗患者的血糖控制与低血糖：一项观察性研究。
J Diabetes Res. 2020 Aug 5;2020:1581726. doi: 10.1155/2020/1581726. eCollection 2020.
8
The role of telehealth during COVID-19 outbreak: a systematic review based on current evidence.新冠疫情期间远程医疗的作用：基于现有证据的系统评价。
BMC Public Health. 2020 Aug 1;20(1):1193. doi: 10.1186/s12889-020-09301-4.
9
Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM Findings from the VIVID Study.U-500R 泵或注射治疗 2 型糖尿病的血糖变异性和时间范围：来自 VIVID 研究的 CGM 结果。
Diabetes Technol Ther. 2021 Jan;23(1):51-58. doi: 10.1089/dia.2020.0030. Epub 2020 Sep 18.
10
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes.1 型糖尿病闭环控制的 6 个月随机、多中心试验。
N Engl J Med. 2019 Oct 31;381(18):1707-1717. doi: 10.1056/NEJMoa1907863. Epub 2019 Oct 16.

迷失在翻译中：科学与医疗保险覆盖标准对连续皮下胰岛素输注的脱节。

Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion.

机构信息

Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

Clinical Research, CGParkin Communications, Inc., Henderson, Nevada, USA.

出版信息

Diabetes Technol Ther. 2021 Oct;23(10):715-725. doi: 10.1089/dia.2021.0196. Epub 2021 Jun 17.

DOI:10.1089/dia.2021.0196
PMID:34077674
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8573795/
Abstract

Numerous studies have demonstrated the clinical value and safety of insulin pump therapy in type 1 diabetes and type 2 diabetes populations. However, the eligibility criteria for insulin pump coverage required by the Centers for Medicare & Medicaid Services (CMS) discount conclusive evidence that supports insulin pump use in diabetes populations that are currently deemed ineligible. This article discusses the limitations and inconsistencies of the insulin pump eligibility criteria relative to current scientific evidence and proposes workable solutions to address this issue and improve the safety and care of all individuals with diabetes.

摘要

大量研究表明胰岛素泵治疗在 1 型和 2 型糖尿病患者中的临床价值和安全性。然而，医疗保险和医疗补助服务中心（CMS）规定的胰岛素泵报销资格所需的明确证据支持目前被认为不合格的糖尿病患者使用胰岛素泵。本文讨论了胰岛素泵资格标准相对于当前科学证据的局限性和不一致性，并提出了切实可行的解决方案，以解决这一问题，提高所有糖尿病患者的安全性和护理水平。